MGMT and glioblastoma: Furthermore, HOTAIRM1 has been associated with shorter survival in glioblastoma patients, independent of IDH mutation and O6-methylguanine-DNA-methyltransferase promoter methylation (Ahmadov et al., 2021), indicating its role as a driver of biological aggressiveness, radioresistance, and poor outcomes in glioblastoma.